The only FDA-approved drug for treating ischemic stroke is intravenous tissue Plasminogen Activator (tPA). The disadvantages of tPA are most apparent in the narrow time frame in which it must be administered, even though it is an effective treatment for stroke when used correctly.
Once the clot is dissolved, there is immediately significantly improved blood flow in the brain, bringing oxygen back up to a normal level. With improved oxygen flow, long-term effects after a stroke are greatly reduced.
For over 90% of the population, tPA is not a viable option, leaving most survivors with only physical and other maintenance therapies to improve their condition after a stroke.
The advantages of cord blood treatment for ischemic stroke
Cord blood treatment for ischemic stroke is a more readily available treatment option than tPA. Instead of only a four-hour window, cord blood has been effective in patients up to five years following their stroke. The greatest chance of improvements using cord blood happens when administered within 10 days of a stroke event. While tPA is not a reliable treatment for most, it is still an effective option when received in a timely manner. Seeking medical attention as soon as possible after a stroke will be key to survival and lessening the long-term effects.
If you or someone you love have suffered a recent stroke, you may be eligible to receive a novelty treatment using cord blood. Get more information about ischaemic stroke treatment at CBC Health.
